NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS

First randomized, double-blind, placebo-controlled trial to demonstrate treatment-associated reduction of TDP-43 in people living with ALS TDP-43 pathology is present in more than 97% of ALS cases and is widely recognized as a central driver of disease progression PrimeC demonstrates...